MX2018001533A - Receptores de antigeno quimerico con funciones controlables integradas. - Google Patents

Receptores de antigeno quimerico con funciones controlables integradas.

Info

Publication number
MX2018001533A
MX2018001533A MX2018001533A MX2018001533A MX2018001533A MX 2018001533 A MX2018001533 A MX 2018001533A MX 2018001533 A MX2018001533 A MX 2018001533A MX 2018001533 A MX2018001533 A MX 2018001533A MX 2018001533 A MX2018001533 A MX 2018001533A
Authority
MX
Mexico
Prior art keywords
present
receivers
antigen
controllable functions
immune cells
Prior art date
Application number
MX2018001533A
Other languages
English (en)
Spanish (es)
Inventor
Duchateau Philippe
Juillerat Alexandre
Poirot Laurent
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis filed Critical Cellectis
Publication of MX2018001533A publication Critical patent/MX2018001533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018001533A 2015-08-24 2016-08-24 Receptores de antigeno quimerico con funciones controlables integradas. MX2018001533A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570545 2015-08-24
EP15202592 2015-12-23
PCT/EP2016/069918 WO2017032777A1 (en) 2015-08-24 2016-08-24 Chimeric antigen receptors with integrated controllable functions

Publications (1)

Publication Number Publication Date
MX2018001533A true MX2018001533A (es) 2018-03-15

Family

ID=56842804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001533A MX2018001533A (es) 2015-08-24 2016-08-24 Receptores de antigeno quimerico con funciones controlables integradas.

Country Status (12)

Country Link
US (1) US10988542B2 (enExample)
EP (1) EP3341410B1 (enExample)
JP (1) JP6894430B2 (enExample)
KR (1) KR20180042361A (enExample)
CN (1) CN107922498A (enExample)
AU (1) AU2016313082B2 (enExample)
BR (1) BR112018002189A2 (enExample)
CA (1) CA2995632C (enExample)
IL (1) IL257138A (enExample)
MX (1) MX2018001533A (enExample)
RU (1) RU2018109426A (enExample)
WO (1) WO2017032777A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
WO2017181119A2 (en) * 2016-04-15 2017-10-19 Novartis Ag Compositions and methods for selective protein expression
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018169948A1 (en) 2017-03-13 2018-09-20 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JOP20180027A1 (ar) * 2017-03-28 2019-01-30 Cell Design Labs Inc بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
US20230192839A1 (en) * 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
JP7555090B2 (ja) * 2017-05-19 2024-09-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞療法を調節するための分子スイッチとしての抗体化学誘導二量体形成化合物（ＡｂＣＩＤ）
US20230159611A1 (en) * 2017-07-03 2023-05-25 Yale University Small molecule adapter regulated, target specific chimeric antigen receptor bearing t cells (smart cars)
CN107312797B (zh) * 2017-07-28 2021-06-18 广州中科蓝华生物科技有限公司 一种蛋白调控系统及其制备方法和应用
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
MA51158A (fr) * 2017-12-14 2020-10-21 Bluebird Bio Inc Récepteurs daric nkg2d
AU2018385699B2 (en) * 2017-12-14 2024-08-15 Regeneron Pharmaceuticals, Inc. Daric interleukin receptors
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
WO2019122188A1 (en) 2017-12-20 2019-06-27 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
WO2019154313A1 (zh) 2018-02-11 2019-08-15 江苏恒瑞医药股份有限公司 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CA3098014A1 (en) * 2018-04-27 2019-10-31 Crispr Therapeutics Ag Anti-bcma car-t-cells for plasma cell depletion
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
MX2021003435A (es) 2018-09-28 2021-06-15 Massachusetts Inst Technology Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
US20220267435A1 (en) * 2018-10-03 2022-08-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
US20210386781A1 (en) 2018-10-05 2021-12-16 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
KR20210124238A (ko) * 2019-01-04 2021-10-14 더 유니버서티 오브 시카고 Ｒｎａ 조절을 위한 시스템 및 방법
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
EP3966242A1 (en) 2019-05-04 2022-03-16 Inhibrx, Inc. Cd123-binding polypeptides and uses thereof
BR112021020999A2 (pt) 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
MX2021013416A (es) 2019-05-04 2021-12-10 Inhibrx Inc Polipeptidos de union al antigeno cd33 y sus usos.
SG11202111890RA (en) * 2019-05-08 2021-11-29 Inhibrx Inc Cd33 targeted immunotherapies
AU2020267559A1 (en) * 2019-05-08 2022-01-06 2Seventy Bio, Inc. CD123 targeted immunotherapies
CA3148027A1 (en) * 2019-05-08 2020-11-12 2Seventy Bio, Inc. Cll-1 targeted immunotherapies
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
WO2021087183A1 (en) * 2019-10-31 2021-05-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
EP4073111A1 (en) * 2019-12-11 2022-10-19 Cilag GmbH International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
EP4168438A4 (en) * 2020-06-22 2024-07-10 Ramot at Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
TW202421651A (zh) * 2022-09-20 2024-06-01 美商達納法伯癌症協會 用於靶向降解及治療劑之遞送之受體介導之胞吞作用
CN119638840A (zh) * 2023-09-15 2025-03-18 东莞市朋志生物科技有限公司 一种抗糖类抗原153的抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530636B2 (en) * 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
KR102332790B1 (ko) 2013-02-15 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
US10287354B2 (en) * 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor

Also Published As

Publication number Publication date
CA2995632A1 (en) 2017-03-02
IL257138A (en) 2018-03-29
EP3341410B1 (en) 2021-06-02
JP6894430B2 (ja) 2021-06-30
AU2016313082A1 (en) 2018-02-15
US20180237533A1 (en) 2018-08-23
CA2995632C (en) 2023-02-07
RU2018109426A3 (enExample) 2020-02-28
US10988542B2 (en) 2021-04-27
BR112018002189A2 (pt) 2018-09-18
WO2017032777A1 (en) 2017-03-02
KR20180042361A (ko) 2018-04-25
RU2018109426A (ru) 2019-09-26
AU2016313082B2 (en) 2022-03-31
EP3341410A1 (en) 2018-07-04
JP2018525006A (ja) 2018-09-06
CN107922498A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
MX2018001533A (es) Receptores de antigeno quimerico con funciones controlables integradas.
CL2018002754A1 (es) Proceso de produccion de raav a base de columnas completamente escalable.
CO2019008946A2 (es) Anticuerpos anti-tgf-beta y su uso
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2016004362A (es) Receptor antigenico quimerico.
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
MX381908B (es) Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
MX2015004420A (es) Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
MX386802B (es) Vectores del factor viii del virus adeno-asociado.
SG10201909716RA (en) Modified j-chain
MX374929B (es) RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
MX2017003557A (es) Celulas t de memoria central para terapia adoptiva de celulas t.
MX2021003169A (es) Metodos para purificar anticuerpos multiespecificos, heterodimericos.
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX2016009965A (es) Produccion de alta titulacion de vectores virales adenoasociados.
CR20240116A (es) RECEPTORES QUIMÉRICOS DE FLT3 Y MÉTODOS DE USO DE LOS MISMOS (Divisional 2018-518)
UY34781A (es) Moduladores de la via del complemento y usos de los mismos
MX382693B (es) Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
AU2016259730A8 (en) Claudin-18.2-specific immunoreceptors and T cell epitopes
PE20161392A1 (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos
MX373779B (es) Receptor quimérico de antígeno anti-cd19 humanizado.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2018005042A (es) Composicion de poliolefina termoplastica (tpo) de flujo elevado con excelente balance de propiedades mecanicas para interiores de automoviles.
WO2013186545A3 (en) Chaperone/usher fusion proteins